IL305665A - Bifunctional conjugates of galactose-deficient immunoglobulins - Google Patents

Bifunctional conjugates of galactose-deficient immunoglobulins

Info

Publication number
IL305665A
IL305665A IL305665A IL30566523A IL305665A IL 305665 A IL305665 A IL 305665A IL 305665 A IL305665 A IL 305665A IL 30566523 A IL30566523 A IL 30566523A IL 305665 A IL305665 A IL 305665A
Authority
IL
Israel
Prior art keywords
optionally substituted
groups
group
moiety
independently
Prior art date
Application number
IL305665A
Other languages
English (en)
Hebrew (he)
Inventor
Gene M Dubowchik
David Spiegel
Reese M Caldwell
Original Assignee
Biohaven Therapeutics Ltd
Gene M Dubowchik
David Spiegel
Reese M Caldwell
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biohaven Therapeutics Ltd, Gene M Dubowchik, David Spiegel, Reese M Caldwell filed Critical Biohaven Therapeutics Ltd
Publication of IL305665A publication Critical patent/IL305665A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
IL305665A 2021-03-10 2022-03-10 Bifunctional conjugates of galactose-deficient immunoglobulins IL305665A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163159383P 2021-03-10 2021-03-10
PCT/US2022/019658 WO2022192478A1 (en) 2021-03-10 2022-03-10 Bifunctional degraders of galactose-deficient immunoglobulins

Publications (1)

Publication Number Publication Date
IL305665A true IL305665A (en) 2023-11-01

Family

ID=83227063

Family Applications (1)

Application Number Title Priority Date Filing Date
IL305665A IL305665A (en) 2021-03-10 2022-03-10 Bifunctional conjugates of galactose-deficient immunoglobulins

Country Status (11)

Country Link
US (2) US20240309114A1 (cg-RX-API-DMAC10.html)
EP (1) EP4304579A4 (cg-RX-API-DMAC10.html)
JP (1) JP2024509282A (cg-RX-API-DMAC10.html)
KR (1) KR20230154900A (cg-RX-API-DMAC10.html)
CN (1) CN116997337A (cg-RX-API-DMAC10.html)
AU (1) AU2022232620A1 (cg-RX-API-DMAC10.html)
BR (1) BR112023017702A2 (cg-RX-API-DMAC10.html)
CA (1) CA3211335A1 (cg-RX-API-DMAC10.html)
IL (1) IL305665A (cg-RX-API-DMAC10.html)
MX (1) MX2023010424A (cg-RX-API-DMAC10.html)
WO (1) WO2022192478A1 (cg-RX-API-DMAC10.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12023553152A1 (en) * 2021-05-17 2024-03-11 Biohaven Therapeutics Ltd Compositions including conjugated therapy enhancers
JP2024524614A (ja) 2021-07-14 2024-07-05 ライシア セラピューティクス, インコーポレイテッド Asgpr細胞表面受容体結合化合物及びコンジュゲート
CN121038815A (zh) * 2023-04-29 2025-11-28 拜奥海芬治疗学有限公司 半乳糖缺陷型免疫球蛋白的双功能降解剂
WO2026083257A1 (en) 2024-10-14 2026-04-23 Biohaven Therapeutics Ltd. Antigen-specific degraders of immunoglobulin a and their uses
WO2026120177A1 (en) 2024-12-06 2026-06-11 Ascendis Pharma A/S Novel long-acting degrader conjugates

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8440191B2 (en) * 2005-11-18 2013-05-14 Tufts Medical Center Clearance of abnormal IGA1 in IGA1 deposition diseases
DK2991683T3 (da) * 2013-05-02 2019-11-04 Glykos Finland Oy Konjugater af et glykoprotein eller en glykan med en toksisk ladning
CA2946064C (en) * 2014-02-21 2023-09-26 Ecole Polytechnique Federale De Lausanne (Epfl) Glycotargeting therapeutics
RU2696490C2 (ru) * 2014-05-19 2019-08-02 Пфайзер Инк. Замещенные-6,8-диоксабицикло[3.2.1.]октан-2,3-диольные соединения в качестве агентов, нацеленных на ASGPR
CA3134610A1 (en) * 2018-04-09 2019-10-17 Yale University Bifunctional small molecules to target the selective degradation of circulating proteins

Also Published As

Publication number Publication date
US20260146106A1 (en) 2026-05-28
JP2024509282A (ja) 2024-02-29
BR112023017702A2 (pt) 2023-12-12
CA3211335A1 (en) 2022-09-15
MX2023010424A (es) 2023-09-18
EP4304579A4 (en) 2026-06-10
US20240309114A1 (en) 2024-09-19
KR20230154900A (ko) 2023-11-09
WO2022192478A1 (en) 2022-09-15
CN116997337A (zh) 2023-11-03
AU2022232620A1 (en) 2023-09-21
EP4304579A1 (en) 2024-01-17

Similar Documents

Publication Publication Date Title
WO2022192478A1 (en) Bifunctional degraders of galactose-deficient immunoglobulins
JP7617974B2 (ja) シクロデキストリンタンパク質薬物コンジュゲート
CN112261954B (zh) 具有针对抗体的亲和性物质和生物正交性官能团的化合物或其盐
KR102938500B1 (ko) 항체 약물 접합제용 친수성 링커
RU2668560C2 (ru) Конъюгированная вакцина на основе пептида антигена wt1
JP7587240B2 (ja) 抗体-ペイロードコンジュゲートの調製のための化合物及びその使用
IL274236A (en) Proline-fastened peptides and their uses
IL274651A (en) Glucocorticoid receptor agonist and immunoconjugates thereof
CN114728073A (zh) 药物从生物活性化合物的内化缀合物的选择性释放
CN120835793A (zh) 用于降解自身抗体的溶酶体靶向双功能分子
CN121038815A (zh) 半乳糖缺陷型免疫球蛋白的双功能降解剂
JP2021513990A (ja) 疎水性アウリスタチンf化合物およびそのコンジュゲート
IL315341A (en) METHOD FOR PRODUCING Fc-CONTAINING MOLECULE
AU2019350536B2 (en) Sulfomaleimide-based linkers and corresponding conjugates
KR20240012381A (ko) 세포독성제를 전달하기 위한 mate 기술을 사용한 항체 약물 접합체
US20240383961A1 (en) Conjugated antibodies for treating diseases
WO2024048490A1 (ja) 変異Fc領域を含む抗体薬物コンジュゲート
KR101536037B1 (ko) 아포리포단백질을 포함하는 항체-약물 결합체
WO2022097500A1 (ja) ペプチド架橋剤及び当該架橋剤で架橋された架橋ペプチド
EP2115001A1 (en) Coupling of antibody polypeptides at the c-terminus
WO2026026939A1 (zh) 抗cd74抗体、抗体-药物缀合物及其制备方法和用途
WO2025111600A1 (en) Compositions and methods for lipidated peptide-based modulators of hla-e
CA3270680A1 (en) ANTIBODY-DRUG CONJUGATE COMPRISING AN ANTI-CLAUDIN 18.2 ANTIBODY AND RELATED THERAPEUTIC USE FOR CANCER
HK40117761A (en) Antibody-drug conjugates targeting folate receptor alpha and methods of use
CN120659785A (zh) Tlr7激动剂及其抗体-药物缀合物